Drug Profile
Insulin - PowderJect Pharmaceuticals
Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator PowderJect Pharmaceuticals
- Developer AlgoRx Pharmaceuticals
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 09 Aug 2002 Discontinued - Preclinical for Diabetes mellitus in United Kingdom (Transdermal)
- 29 Mar 2002 PowderJect Pharmaceuticals has sold its non-vaccine business to AlgoRx
- 17 Jan 2002 PowderJect Pharmaceuticals intends to license out the drug applications of its powder injection technology